Compare GSK plc (GSK) vs ThredUp Inc (TDUP) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

ThredUp (TDUP) trades at $6.75, up 6.47% today, with a bullish technical signal from moving averages. The company shows improving fundamentals with Q1 2026 revenue growth of 15% year-over-year to $81.7M and a strong gross margin of 79.4%. Recent developments include the launch of a peer-to-peer marketplace and AI-powered shopping tools. Analyst sentiment remains positive with 57% buy ratings and a $6.90 consensus price target, though the company continues to report net losses.

TDUP presents a turnaround story with improving revenue trends and cost management, but profitability remains elusive. The stock offers potential upside to analyst targets if execution continues, though risks include persistent losses, competitive pressures, and the need to achieve sustainable positive EBITDA. Current valuation at 2.58x sales appears reasonable for the growth trajectory.